tbuckley/cabot-search huggingface dataset:
From the FDA
Authors: None s
Journal: JAMA (1985)

<h3>Health Fraud Alleged:</h3> Last year, FDA personnel began undercover surveillance of exhibitors at a "Health Horizon Positive Living Expo" held at a Washington, DC, hotel. On May 16, the FDA's Fraud Branch sent regulatory letters to 13 of those exhibitors citing them for misbranding, false and misleading labeling, and selling unapproved new drugs claimed by their promoters to be useful in treating cancer, hypertension, depression, and a host of other conditions. The FDA said further action will be taken against promoters who disregard the regulatory letters and that they propose to continue the investigation at any future Health Horizon Positive Living Expos. <h3>Approved Drugs List:</h3> The FDA annually publishes (in October) a list of prescription drug products currently marketed in the United States that have been approved by the agency as safe and effective. The list, which is updated monthly by cumulative supplements, also contains therapeutic equivalence evaluations for multisource
CONSORT 2010 statement: extension checklist for reporting within person randomised trials
Authors: Nikolaos Pandis, Bryan Chung, Roberta W Scherer, Diana Elbourne, Douglas G Altman
Journal: BMJ (2017)

Evidence shows that the quality of reporting of randomised controlled trials (RCTs) is not optimal. The lack of transparent reporting impedes readers from judging the reliability and validity of trial findings and researchers from extracting information for systematic reviews and results in research waste. The Consolidated Standards of Reporting Trials (CONSORT) statement was developed to improve the reporting of RCTs. Within person trials are used for conditions that can affect two or more body sites, and are a useful and efficient tool because the comparisons between interventions are within people. Such trials are most commonly conducted in ophthalmology, dentistry, and dermatology. The reporting of within person trials has, however, been variable and incomplete, hindering their use in clinical decision making and by future researchers. This document presents the CONSORT extension to within person trials. It aims to facilitate the reporting of these trials. It extends 16 items of the CONSORT 2010 checklist and introduces a modified flowchart and baseline table to enhance transparency. Examples of good reporting and evidence based rationale for CONSORT within person checklist items are provided.
Correlation Among Cancer Incidence and Mortality Rates and Internet Searches in the United States
Authors: Mackenzie R. Wehner, Kevin T. Nead, Eleni Linos
Journal: JAMA Dermatology (2017)

Population-level disease metrics are critical to guide the distribution of resources and implementation of public health initiatives. Internet search data reflect population interest in health topics and may be an alternative metric of disease characteristics when traditional sources are lacking, such as in basal and squamous cell carcinomas, which are not included in national cancer registries. However, these data are not yet well validated or understood.To evaluate whether state-specific normalized internet search volume correlates with incidence and mortality rates of common cancers in the United States, including melanoma.This was a cross-sectional analysis of Google search volume index data and US cancer incidences and mortalities of 8 of the most incident cancers in the United States in 2009 to 2013, at the state level, per the National Program of Cancer Registries. Participants were people performing Google searches and patients diagnosed as having cancers reported to cancer registries.Correlation between Google search volumes, normalized to total Google search volume, and National Program of Cancer Registries recorded cancer incidence and mortality rates.By state, relative Google search volume statistically significantly correlated with cancer incidence rates in 5 of 8 commonly diagnosed cancers in the United States (colon cancer: R = 0.61; P < .001; lung cancer: R = 0.73; P < .001; lymphoma: R = 0.51; P < .001; melanoma: R = 0.36; P = .01; and thyroid cancer: R = 0.30; P = .03). For 4 of those 5 cancers (colon cancer: R = 0.61; P < .001; lung cancer: R = 0.62; P < .001; lymphoma: R = 0.38; P = .006; and melanoma: R = 0.31; P = .03), relative Google search volume also correlated with mortality rates.Population-level internet search behavior may be a valuable real-time tool to estimate cancer incidence and mortality rates, especially for cancers not included in national registries, such as basal and squamous cell carcinomas.
Treating Anxiety in 2017
Authors: Murray B. Stein, Michelle G. Craske
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Left Ventricular Assist Device Malfunctions
Authors: Robert L. Kormos, Michael McCall, Andrew Althouse, Luigi Lagazzi, Richard Schaub, Michael A. Kormos, Jared A. Zaldonis, Christopher Sciortino, Kathleen Lockard, Nicole Kuntz, Elizabeth Dunn, Jeffrey J. Teuteberg
Journal: Circulation (2017)

Background: Reports of left ventricular assist device (LVAD) malfunction have focused on pump thrombosis. However, the device consists of the pump, driveline, and peripherals, all of which are potentially subject to failure. Methods: Prospectively collected data were reviewed for all LVAD device malfunctions (DMs) occurring in rotary LVADs implanted at a single center between April 2004 and May 2016. Durable LVADs included 108 Heartmate II (HM II) and 105 HeartWare VAD (HVAD). DM data were categorized according to device type and into categories related to the component that failed: (1) controller, (2) peripheral components, and (3) implantable blood pump or its integral electric driveline. Pump-related events were analyzed as pump-specific (suspected or confirmed thrombosis) or nonpump-specific (driveline failure). DM rates were reported as events per 1000 patient-days, and Cox proportional hazard models were used for time-to-event analyses. Cumulative rates of malfunction were examined for the main components of each type of LVAD. Results: Types of DM included controller failure (30%), battery failure (19%), or patient cable failure (14%), whereas only 13% were because of pump failure. DMs were more common in the HM II device (3.73 per 1000 patient-days versus 3.06 per 1000 patient-days for the HVAD, P &lt;0.01). A higher rate of pump-specific malfunctions was discovered in those implanted with an HM II versus an HVAD (0.55 versus 0.39, respectively; P &lt;0.01) and peripheral malfunctions (2.32 versus 1.78 for the HM II and HVAD, respectively; P &lt;0.01); no difference occurred in the incidence of controller DM between the 2 LVADs. Patients with HVAD were 90% free of a pump-specific malfunction at 3 years compared with 56% for the HM II (log-rank P &lt;0.003). Only 74% of the patients with HM II were free of pump thrombosis at 3 years compared with 90% of the patients with HVAD. Freedom from failure of the integrated driveline was 79% at 3 years for the HM II but 100% for the HVAD (log-rank P &lt;0.02). Conclusions: Device malfunction is much broader than pump failure alone and occurs for different components at different rates based on the type of LVAD.
Accelerating clinical trial enrollment with comprehensive genomic profiling (CGP) and just-in-time clinical trial sites: An index case of a paradigm shift.
Authors: Gaurav Singal, Deepu Madduri, Lara Yuan, David Luo, Aparna Upadhyay, Matthew B. Wiener, Seth Andrew Wander, Eric B. Lynam, David Bourque, Alex Parker, Rob Manor, Will McCarthy, Edna Chow Maneval, Siraj Mahamed Ali, Vincent A. Miller
Journal: Journal of Clinical Oncology (2017)

6539 Background: In many instances, trials may offer the best or only therapeutic option for patients with rare findings. However, conducting clinical trials of novel therapeutics targeting rare molecular variants is challenging. Patient populations are small, distributed, and predominantly in community settings where trial access remains limited by awareness and site availability. These challenges increase costs of drug development and approval, delaying widespread patient access. Methods: Foundation Medicine deployed a trial education and access program, “Precision Enrollment,” with Ignyta (a trial sponsor) and Pharmatech (a site management organization, or SMO, enabling “Just-In-Time” clinical trials) (Wiener, JCO 2007). Infrastructure and algorithms developed at Foundation Medicine (“SmartTrials Engine”) matched sequenced patients (avg n = 800/wk) with activating NTRK, ROS1, or ALK fusions to the phase II study of Entrectinib (NCT02568267). Oncologists at Foundation Medicine, through peer-to-peer outreach, facilitated trial access by providing trial and nearest site information to treating providers of matched patients. Results: 107 treatment-eligible patients with NTRK, ROS1, or ALK fusions were matched by the SmartTrials Engine; 36 (33%) expressed interest in trial participation. One such patient with NSCLC and a CD74-ROS1 fusion was unable to participate at an open trial site due to inability to travel. The patient’s site was part of the “Just-In-Time” network, with IRB and contract pre-approval, and was activated in only 3 days. Total time from patient identification to initiation of therapy was 7 days. Conclusions: We demonstrate a novel methodology for patient matching to trials targeting rare genomic findings, including in community settings. If extended, such innovative partnerships combined with computational matching infrastructure, could improve drug development and therapeutic access.
Complete Laparoscopic Management of Cholecystocutaneous Fistula, a Rare Case Report
Authors: AH Malik, M Nadeem, J Ockrem
Journal: Endoscopy (2006)

Aims: Cholecysto-cutaneous fistula is very rare in modern day surgical practice and is usually dealt by open surgery. We report a 76 year old lady who was managed completely laparoscopically.
Long-Term Results on Outcome of Children with Hematological Malignancies Transplanted from an Unrelated Donor Enrolled in an Open Label, Randomized Trial Comparing Two Different Dosages of Rabbit Anti-Thymocyte Globulin
Authors: Franco Locatelli, Maria Ester Bernardo, Alice Bertaina, Carla Rognoni, Patrizia Comoli, Attilio Rovelli, Andrea Pession, Franca Fagioli, Claudio Favre, Edoardo Lanino, Giovanna Giorgiani, Pietro Merli, Arcangelo Prete, Marco Zecca
Journal: Blood (2016)
11q deletion in neuroblastoma: a review of biological and clinical implications
Authors: Vid Mlakar, Simona Jurkovic Mlakar, Gonzalo Lopez, John M. Maris, Marc Ansari, Fabienne Gumy-Pause
Journal: Molecular Cancer (2017)

Deletion of the long arm of chromosome 11 (11q deletion) is one of the most frequent events that occur during the development of aggressive neuroblastoma. Clinically, 11q deletion is associated with higher disease stage and decreased survival probability. During the last 25 years, extensive efforts have been invested to identify the precise frequency of 11q aberrations in neuroblastoma, the recurrently involved genes, and to understand the molecular mechanisms of 11q deletion, but definitive answers are still unclear. In this review, it is our intent to compile and review the evidence acquired to date on 11q deletion in neuroblastoma.
CRY1/2 Selectively Repress PPARδ and Limit Exercise Capacity
Authors: Sabine D. Jordan, Anna Kriebs, Megan Vaughan, Drew Duglan, Weiwei Fan, Emma Henriksson, Anne-Laure Huber, Stephanie J. Papp, Madelena Nguyen, Megan Afetian, Michael Downes, Ruth T. Yu, Anastasia Kralli, Ronald M. Evans, Katja A. Lamia
Journal: Cell Metabolism (2017)
THREE-DIMENSIONAL IN-VIVO SCAPULAR KINEMATICS AND SCAPULOHUMERAL RHYTHM: A COMPARISON BETWEEN ACTIVE AND PASSIVE MOTION
Authors: Doo-Sup Kim
Journal: British Journal of Sports Medicine (2017)

Background This study set out to offer a three-dimensional description of scapular kinematics and scapulohumeral rhythm (SHR) of healthy subjects during arm elevation and lowering, as well as to compare and analyse the differences between active and passive motion of the shoulder. Methods The study examined the shoulders of ten healthy males (mean age: 23.5 years). The shoulders of the ten healthy participants were elevated and lowered while fluoroscopic images were taken, and three-dimensional bone models were created from 2D to 3D using model registration techniques. The Euler angle sequences of the models' scapular kinematics and SHR were compared during active and passive shoulder motion. Results The scapula presented three-way movements of upward rotation, posterior tilting, and external rotation during arm elevation and lowering. During arm elevation, upward rotation showed a statistically significant difference between active and passive shoulder movements (p&lt;0.05). Upward rotation between 45° and 90° showed a statistically significant difference (p&lt;0.05). The scapular posterior tilting from the active motion resulted in more tilting in the high-degree range of motions. Additionally, statistically significant differences were found between active and passive motion (p&lt;0.05). There was no statistically significant difference between the two groups during external rotation. However, during arm lowering, the scapular upward rotation showed a statistically significant difference between active and passive motion (both p&lt;0.05). Conclusions In healthy subjects, scapular kinematics showed a statistically significant difference between active and passive motion during elevation in the higher range of motion, but not during lowering. In terms of upward rotation, active shoulders rotated more upward during arm elevation. There was more upward rotation in active shoulders during arm elevation. With regard to passive motion, there was more posterior tilting during arm elevation. The scapular kinematics of upward rotation and posterior tilting showed a linear rotation during arm lowering.
Is Cardioprotection Dead?
Authors: David J. Lefer, Eduardo Marbán
Journal: Circulation (2017)

For >4 decades, the holy grail in the treatment of acute myocardial infarction has been the mitigation of lethal injury. Despite promising initial results and decades of investigation by the cardiology research community, the only treatment with proven efficacy is early reperfusion of the occluded coronary artery. The remarkable record of failure has led us and others to wonder if cardioprotection is dead. The path to translation, like the ascent to Everest, is certainly littered with corpses. We do, however, highlight a therapeutic principle that provides a glimmer of hope: cellular postconditioning. Administration of cardiosphere-derived cells after reperfusion limits infarct size measured acutely, while providing long-term structural and functional benefits. The recognition that cell therapy may be cardioprotective, and not just regenerative, merits further exploration before we abandon the pursuit entirely.
Abstract 82: Mnsodtg Mice Exhibit Improved Heart and Mitochondrial Function During Chronic Chagas Disease
Authors: Jianjun Wen, Craig Porter, David Herndon, Nisha J Garg
Journal: Circulation Research (2015)

Background: We observed that mitochondrial reactive oxygen species (mtROS) plays very important roles in the pregression of chagesic disease (CD). In this study, we utilized genetically-modified mice to scavenge mtROS to investigate the impact of improved ROS scavenging capacity on heart function in CD. Methods and Results: C57BL/6 mice (wild-type, MnSODtg, MnSOD+/-) were infected with Trypanosoma cruzi(Tc). Chronically infected mice (≥120dpi) exhibited a substantial decrease in heart tissue MnSOD gene expression, protein level, enzyme activity and antioxidant level; decrease of heart dysfunction via lower of SV, CO, EF, FS and LVPW,s, and increase of ESV/EDS and LVID;s; enhancement of hypertrophy by increase of IVS, LV mass and areas duo to augmentation of collagen expressions. One of our novel observations was that sarco/endoplasmic reticulum Ca2+-ATPase (SERCA2) lost its role of maintenance of low cytoplasm free calcium and mediated calcium uptake to intracellular store in Tc-induced chronic chagasic disease. Studies of fresh heart slices using O2K confirmed that Tc diminished heart mitochondrial function like decrease of oxygen flux and respiratory control ratio (RCR), which were caused by enhancements of ROS. Myocardial mitochondrial damage was pronounced and associated with a &gt;x% decline in mitochondrial oxygen flux in chronically infected wild-type and MnSOD transgenic mice. Imaging of intact heart for cardiomyocytes and collagen by the nonlinear optical microscopy techniques showed significant increase in collagen (&gt;x0-fold) in chronically infected wild-type mice; while MnSODtg mice exhibited a basal increase in collagen that did not change during chronic phase. Chronically infected MnSODtg mice exhibited a marginal decline in Tc-induced heart function, heart hypertrophy, mitochondrial dysfunction Conclusions: Overexpression of MnSOD inhibited Tc-induced oxidative damage od heart tissue. , suggesting that enhancing the mitochondrial ROS scavenging capacity was beneficial in controlling the inflammatory and oxidative pathology, and cardiac remodeling responses that are hallmarks of chronic Chagas disease.
Successful endoscopic closure of a refractory button-battery tracheoesophageal fistula in a 3-year child using endoscopic submucosal dissection of the surrounding mucosa
Authors: Melissa Gruner, Sophie Heissat, Vincent Pitiot, Paul Suy, Alain Lachaux, Thierry Ponchon, Mathieu Pioche
Journal: Endoscopy (2017)

Most serious button-battery ingestions are not witnessed and they can cause life threatening complications.
Immunologic and objective tumor responses to PEGylated human IL-10 (AM0010) with 5-FU/LV and oxaliplatin (FOLFOX) in metastatic pancreatic adenocarcinoma (PDAC)
Authors: Hecht J. Randolph, Aung Naing, Gerald Falchook, Manish Patel, Jeffrey Infante, Raid Aljumaily, Wong Deborah, Karen Autio, Zev Wainberg, Milind Javle, Johanna Bendell, Shubham Pant, Annie Hung, Peter Van Vlasselaer, Gail Brown, Martin Oft, Kyriakos Papadopoulos
Journal: Annals of Oncology (2017)
The Epidemiology of Hepatitis B Virus Infection
Authors: I un-Nabi, S Jibodh, V Trimble, B Crowley, S Mckiernan, S Norris
Journal: Endoscopy (2006)

Ireland was historically considered to be a country of low endemnicity (HBsAg+<2%) but a 20-fold increase in HBV notification rates has recently been reported (HPSC-2005). While increased screening rates may account for some of this change, the increase may also reflect the chainging demography of Irish society.
Long noncoding RNA MRCCAT1 promotes metastasis of clear cell renal cell carcinoma via inhibiting NPR3 and activating p38-MAPK signaling
Authors: Jia-Kuan Li, Cheng Chen, Jia-Yi Liu, Jia-Zi Shi, Shu-Peng Liu, Bing Liu, Deng-Shuang Wu, Zi-Yu Fang, Yi Bao, Ming-Ming Jiang, Ji-Hang Yuan, Le Qu, Lin-Hui Wang
Journal: Molecular Cancer (2017)

Recent evidences showed that long noncoding RNAs (lncRNAs) are frequently dysregulated and play important roles in various cancers. Clear cell renal cell carcinoma (ccRCC) is one of the leading cause of cancer-related death, largely due to the metastasis of ccRCC. However, the clinical significances and roles of lncRNAs in metastatic ccRCC are still unknown. lncRNA expression microarray analysis was performed to search the dysregulated lncRNA in metastatic ccRCC. quantitative real-time PCR was performed to measure the expression of lncRNAs in human ccRCC samples. Gain-of-function and loss-of-function experiments were performed to investigate the biological roles of lncRNAs on ccRCC cell proliferation, migration, invasion and in vivo metastasis. RNA pull-down, RNA immunoprecipitation, chromatin immunoprecipitation, and western blot were performed to explore the molecular mechanisms underlying the functions of lncRNAs. The microarray analysis identified a novel lncRNA termed metastatic renal cell carcinoma-associated transcript 1 (MRCCAT1), which is highly expressed in metastatic ccRCC tissues and associated with the metastatic properties of ccRCC. Multivariate Cox regression analysis revealed that MRCCAT1 is an independent prognostic factor for ccRCC patients. Overexpression of MRCCAT1 promotes ccRCC cells proliferation, migration, and invasion. Depletion of MRCCAT1 inhibites ccRCC cells proliferation, migration, and invasion in vitro, and ccRCC metastasis in vivo. Mechanistically, MRCCAT1 represses NPR3 transcription by recruiting PRC2 to NPR3 promoter, and subsequently activates p38-MAPK signaling pathway. MRCCAT1 is a critical lncRNA that promotes ccRCC metastasis via inhibiting NPR3 and activating p38-MAPK signaling. Our results imply that MRCCAT1 could serve as a prognostic biomarker and therapeutic target for ccRCC.
Clinicopathological factors influence diagnostic accuracy of clinical N staging for early gastric cancer
Authors: A. Grothey, M. Shah, T. Yoshino, E. Van Cutsem, J. Taieb, R. Xu, N.C. Tebbutt, A. Falcone, A. Cervantes, L. Borodyansky, C.J. Li
Journal: Annals of Oncology (2017)